Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs

In this articleMRKBMYJNJThe New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium. NYSEBig pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a so-called patent cliff.That refers to when a company's patents for one or more leading branded products expire, which opens the door for competitors to sell copycats of thos ...